RxDoctor Payments Data

Raymond Khouw, MD

Obstetrics & Gynecology · Dallas, TXNPI 1174603500

Payments from drug & device makers

$2,464in general payments, 2019–2025

Across 39 payments — averaging $63.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$529
  • Lupin Inc.$338
  • Novo Nordisk$333
  • AbbVie$247
  • Therapeuticsmd, Inc.$224
  • Astellas Pharma US Inc$180
  • plus $612 from 7 others

What the payments were for

  • Food & beverage$2,28493%
  • Education$1807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,464 in reported general payments places this provider in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.

See all obstetrics & gynecology providers in Texas

Medicare billing

Part B allowed, 2024
$2,759
Medicare patients
27
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$22,344
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid16$2,195
Alendronate Sodium145$1,493
Estradiol78$841
Rosuvastatin Calcium60$833
Risedronate Sodium15$832
Amlodipine Besylate73$695
FenofibrateFenofibrate Nanocrystallized14$672
Metoprolol Succinate35$669
Nifedipine ErNifedipine16$551
Pravastatin Sodium23$517
ValacyclovirValacyclovir Hcl12$507
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide17$466
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide24$434
Nebivolol Hcl14$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$333$22,34420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.

Other obstetrics & gynecology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →